Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
- PMID: 15743540
- PMCID: PMC555600
- DOI: 10.1186/1471-2407-5-25
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
Abstract
Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets.
Methods: Paraffin embedded archival material from 81 patients diagnosed with CUP was used. Tumor histology was adenocarcinoma (77%), undifferentiated carcinoma (18%) and squamous cell carcinoma (5%). The tissue expression of CD34, VEGF and TSP-1 was assessed immunohistochemically by use of specific monoclonal antibodies and was analyzed against clinicopathological data.
Results: VEGF expression was detected in all cases and was strong in 83%. Stromal expression of TSP-1 was seen in 80% of cases and was strong in 20%. The expression of both proteins was not associated with any clinical or pathological parameters. Tumor MVD was higher in tumors classified as unfavorable compared to more favorable and was positively associated with VEGF and negatively with TSP-1.
Conclusion: Angiogenesis is very active and expression of VEGF is almost universal in cancers of unknown primary. These findings support the clinical investigation of VEGF targeted therapy in this clinical setting.
Figures
Similar articles
-
Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma.Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:241-6. doi: 10.1111/j.1525-1438.2006.00316.x. Int J Gynecol Cancer. 2006. PMID: 16515598
-
Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance.Oncol Rep. 2006 Mar;15(3):525-32. Oncol Rep. 2006. PMID: 16465407
-
Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.Pathol Res Pract. 2009;205(12):854-7. doi: 10.1016/j.prp.2009.07.015. Epub 2009 Sep 16. Pathol Res Pract. 2009. PMID: 19762163
-
[2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary].Rev Esp Patol. 2019 Jan-Mar;52(1):33-44. doi: 10.1016/j.patol.2018.08.002. Epub 2018 Oct 10. Rev Esp Patol. 2019. PMID: 30583830 Review. Spanish.
-
The current evidence for a biomarker-based approach in cancer of unknown primary.Cancer Treat Rev. 2018 Jun;67:21-28. doi: 10.1016/j.ctrv.2018.04.011. Epub 2018 May 2. Cancer Treat Rev. 2018. PMID: 29751335 Review.
Cited by
-
[Peritoneal carcinomatosis secondary to CUP syndrome : Diagnosis and indications for multimodal treatment].Radiologie (Heidelb). 2023 May;63(5):371-380. doi: 10.1007/s00117-023-01140-9. Epub 2023 Apr 6. Radiologie (Heidelb). 2023. PMID: 37022459 Review. German.
-
Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.Front Pharmacol. 2023 Jan 23;14:997760. doi: 10.3389/fphar.2023.997760. eCollection 2023. Front Pharmacol. 2023. PMID: 36755949 Free PMC article.
-
Study of angiogenesis in invasive breast carcinoma by morphometry and immunohistochemistry.Med J Armed Forces India. 2022 Jul;78(3):345-354. doi: 10.1016/j.mjafi.2021.10.013. Epub 2021 Dec 16. Med J Armed Forces India. 2022. PMID: 35855704 Free PMC article.
-
A Systematic Review of Cancer of Unknown Primary in the Head and Neck Region.Cancer Manag Res. 2021 Sep 18;13:7235-7241. doi: 10.2147/CMAR.S319179. eCollection 2021. Cancer Manag Res. 2021. PMID: 34566429 Free PMC article. Review.
-
The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.Front Oncol. 2020 May 8;10:533. doi: 10.3389/fonc.2020.00533. eCollection 2020. Front Oncol. 2020. PMID: 32457826 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
